Diagnosis and treatment progress of Waldenstr?m macroglobulinemia
10.3760/cma.j.cn115356-20200918-00228
- VernacularTitle:华氏巨球蛋白血症诊治进展
- Author:
Jingjing DENG
1
;
Wenming CHEN
Author Information
1. 首都医科大学附属北京朝阳医院血液科 100020
- From:
Journal of Leukemia & Lymphoma
2020;29(11):645-647
- CountryChina
- Language:Chinese
-
Abstract:
The 25th Congress of the European Hematological Society (EHA) was held in the form of a virtual edition from June 11 to 21, 2020, which focused on the significance of the detection of MYD88 and CXCR4 mutations in Waldenstr?m macroglobulinemia (WM) patients by using circulating free DNA (cfDNA), as well as the clinical results of Bruton tyrosine kinase inhibitors and treatment regimen including rituximab in the front-line and relapsed WM patients.
